Pulmonx is the global leader in interventional procedures for the treatment of COPD. It develops and markets non-surgical technologies for the assessment and treatment of patients with severe emphysema, a progressive and life-threatening form of COPD. The Pulmonx solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The technology is supported by a compelling body of clinical evidence including over 100 published scientific articles regarding the clinical benefits of Zephyr Valves. FDA granted the Zephyr Valve a ‘breakthrough device’ designation, and in June 2018 Pulmonx received FDA pre-market approval to commercialize our Zephyr Valve. The Zephyr Valve is now commercially available and physicians in more than 25 countries around the world routinely use the Zephyr Valves to improve the lives of patients with severe emphysema, with over 76,000 valves used to treat more than 19,000 patients worldwide to date.

Part of Medtronic Plc, Covidien Pte Ltd. is a Singaporean company located in Singapore that manufactures and supplies medical equipment.

Sichuan Anchuang Environmental Protection Technology Co., Ltd., established on 2014-04-28, Business scope includes research and development,manufacture(In the industrial industry, set up another branch for operation or choose another business site for operation),Sell ​​special equipment for environmental protection and provide technical services;Environmental Engineering Design,construction(Operating with a qualification certificate);Environmental Pollution Control;Environmental Technology Consulting;Production of plastic woven bags(In the industrial industry, set up another branch for operation or choose another business site for operation)and sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Emphasys Medical, Inc., a medical technology company, focuses on developing and commercializing minimally invasive therapeutic devices for the treatment of patients with emphysema and other breathing disorders. It offers Zephyr Endobronchial Valve system, which is designed to block air from passing through the opening in the lung and into the chest cavity, resulting in the reduction or elimination of airflow through the leak to allow the tissue to heal. The company offers its products through distributors and dealers in Europe, Australia, Hong Kong, and Singapore. Emphasys Medical was founded in 2000 and is based in Redwood City, CA. Emphasys Medical, Inc. operates as a subsidiary of Pulmonx Corp.

Broncus Technologies is a medical technology company focused on developing minimally-invasive medical devices for emphysema and other lung diseases. Broncus is investigating the Exhale emphysema product line to perform our patented treatment method called Airway Bypass. Airway Bypass could be the first minimally-invasive procedure for the treatment of homogeneous, or diffuse, emphysema, which constitutes the majority of the emphysema patient population. Broncus is currently enrolling patients worldwide in our pivotal EASE Trial investigating a treatment of severe homogeneous emphysema. Broncus is located in Mountain View, CA (San Francisco Bay area). Broncus International is located in Nyon, Switzerland.

Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Kimberly-Clark Corp. engages in the manufacture and marketing of products made from natural or synthetic fibers. It operates through the following segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, training and youth pants, swim pants, baby wipes, feminine and incontinence care products, and other related products. The Consumer Tissue segment produces and sells facial and bathroom tissue, paper towels, napkins, and related products for household use. The K-C Professional segment supplies workplace supporting products such as wipers, tissue, towels, apparel, soaps, and sanitizers. The company was founded by John A. Kimberly, Havilah Babcock, Charles B. Clark, and Frank C. Shattuck in 1872 and is headquartered in Irving, TX.

Pharmaceuticals

Senko MIM is primarily engaged in manufacturing medical, surgical, ophthalmic, and veterinary instruments and apparatus. They are the leading medical device company with over 80 years of experience in Japan and have pursued high-quality medical devices as both importer and manufacturer. The wide range of products based on the four core pillars allows them to build relationships with many types of hospitals and medical institutes all over Japan. They aim to provide high-quality medical devices and are always open to listening to demands from their future partners.

Portaero, Inc develops device used to treat chronic obstructive pulmonary diseases. The company was formerly known as Respira Inc. The company was incorporated in 2007 and is based in Cupertino, California.

Philips Electronics Ltd. manufactures and distributes lighting products. Its products include incandescent and halogen, compact and standard fluorescent, automotive, high intensity gas discharge and special lamps, fixtures, and advance ballasts. The company offers lighting applications such as downlights, spotlights, and wall washing. Philips Electronics was founded in 1934 and is headquartered in Markham, Canada.

Free Flow Medical develops a next-generation medical device to treat patients with emphysema, an advanced form of chronic obstructive disease (COPD) that severely limits the quality of life, presents the patient with ongoing severe breathlessness and eventual mortality. The company's technology includes a minimally-invasive tool that helps prevent shortness of breath, enabling doctors to help treat patients suffering from emphysema. It incubates inside the Spin-Off Factory and is the first company to be spun out.

Hoechst AG produced specialty chemicals and pharmaceutical products. It products ranged in areas of heart cycle, thrombose, central nervous system, onkologie, diabetes, metabolic illnesses, internal medicine and vaccines. Founded in 1863, the company was headquartered in Frankfurt am Main, Germany.

Spiration, Inc., doing business as Olympus Respiratory America, develops medical devices for the treatment of air leaks and lung diseases. The company was founded in 1999 and is based in Redmond, Washington. As of 2010, Spiration, Inc. operates as a subsidiary of Olympus America Inc.

Traxtal, Inc., part of Koninklijke Philips NV, is a company headquartered in Toronto, ON, Canada, that manufactures minimally-invasive medical instruments. Koninklijke Philips NV acquired Traxtal, Inc. on May 04, 2009.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Aeris Therapeutics is dedicated to the development and commercialization of innovative therapies that improve the lives of patients with emphysema and other advanced lung diseases. We pursue this mission by maintaining our commitment to scientific excellence and the highest quality standards. Our company possesses a fundamental core competence in pulmonary medicine with substantial capabilities in preclinical and clinical research, product development and commercialization.

Jiangsu Mitsui Environmental Protection Co., Ltd. is a national high-tech enterprise specializing in the design and manufacture of incinerators, RTO thermal storage incinerators, waste gas concentration thermal storage incinerators, rotary kiln incinerators, dust removal, desulfurization and denitration and other three waste incineration treatment equipment, which is leading the domestic three waste incineration treatment system to solve today's industrial environmental pollution. In view of the seriousness and urgency of the current industrial three wastes pollution in China, the company has introduced the latest advanced incineration technology from Japan, Europe and the United States through careful research on the international advanced three wastes treatment technology, and successfully cooperated with the Spanish 3E Group in an all-round strategic way. The incinerator designed and developed professionally has won more than 20 national invention and utility model patents, and won the title of * * * new product and provincial high-tech product. Mitsui Environmental Protection has a technical team led by postdoctoral scholars, and has cooperated with four key universities in China. Over the years, the company has actively explored and developed the comprehensive treatment of three wastes, and has accumulated rich experience. Realize a one-stop process from design, production, installation, commissioning to after-sales service. Through the research and development of international advanced treatment methods for the concentration and heat storage of organic waste gas, incineration and waste heat recovery, and through the means of drying, incineration and purification of industrial hazardous waste, the toxic and harmful substances in hazardous waste will be completely destroyed, so as to show the ultimate goal of "reduction, harmless and recycling", while taking the collection and reuse of intermediate energy as the development direction, fully reflecting the value of circular economy. Mitsui Environmental Protection Development has the following incinerators: factory waste gas direct combustion incinerator, factory waste gas heat storage incinerator, factory waste gas catalytic oxidation system, factory waste gas purification system, industrial and medical hazardous waste incinerator, hazardous waste pyrolysis and gasification furnace, general solid waste incinerator (animal carcasses, medical waste, etc.), electronic hazardous waste incinerator and recovery system, chemical and biochemical sludge incinerator treatment system Solid liquid gas integrated treatment incinerator system, hazardous waste water and waste liquid incinerator treatment system, spray adsorption device system

Changzhou Jintan Tiansheng Machinery Manufacturing Co., Ltd., established on 2002-11-06, Business scope includes machinery and equipment manufacturing,Sales;Mechanical parts processing,Sales;Self-operated and agent import and export business of various commodities and technologies.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)